Clinical report: Akero’s efruxifermin shows deepening treatment effect at 96 weeks

A 96-week readout in a Phase IIb study of Akero’s MASH therapy showed a deepening treatment effect over time, boosting confidence in the therapy’s prospects in an ongoing Phase III study — and setting the stage for a nine-digit follow-on.

The HARMONY study of FGF21 agonist efruxifermin from Akero Therapeutics Inc. (NASDAQ:AKRO) had already met its primary endpoint in 2022, with the trial’s two doses leading to improvements in at least one stage of fibrosis in 41% and 39% of patients at week 24, compared with with 20% for placebo (p<0.05)...